Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/1278"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label | |
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_value | |
| dc:creator | |
| dc:date |
"10/29/2007 12:36:05"
|
| ?:content |
"Route of administration: oral
study duration: volunteers received either 200 mg itraconazole or placebo orally once a day for 4 days. On day 4, each subject ingested a single 40 mg dose of pravastatin (study II).
population: 10 : 7 male, 3 female
ages:19-29
RESULTS:
In study II, itraconazole slightly increased the AUC(0-infinity) and Cmax of pravastatin, but the changes were statistically nonsignificant (p = 0.052 and 0.172, respectively). The t1/2 was not altered. The AUC(0-infinity) and Cmax of HMG-CoA reductase inhibitors were increased less than twofold (p < 0.05 and p = 0.063, respectively) by itraconazole.
NOTE: a statistically significant increase in HMG-CoA inhibitors occured but we cannot distinguish which metabolites of pravastatin were increased from the study"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ itraconazole_increases_auc_pravastatin, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1103 }